Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case Report
Minimal Residual Disease
DOI:
10.3389/fimmu.2023.1254010
Publication Date:
2023-09-29T09:10:00Z
AUTHORS (11)
ABSTRACT
Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has cured many patients with malignant hematologic diseases such as mixed phenotype acute leukemia (MPAL), while those relapsing after allo-HSCT still exhibit high mortality, poor prognosis, and no standard treatment modalities. It is necessary to explore more therapeutic modalities for post-transplant relapse obtain a better prognosis. Case presentation In this case report, young male MPAL received reaching complete remission (CR) by induction chemotherapy. Unfortunately, of both myeloid T lineages occurred nine months later. After receiving demethylating chemotherapy, lineage measurable residual disease (MRD) turned negative. T-lineage MRD negative CD7-targeted chimeric antigen receptor (CAR)-T therapy. The bone marrow remained MRD-negative 4 months. This preliminarily demonstrated long-lasting CR CAR-T therapy, allowing Conclusion Demethylating drugs combined therapy feasible in treating transplantation, good efficacy safety, which will be promising option MPAL.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (17)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....